Blueprint Medicines — CTOS 2018 Annual Meeting
33 slides from Blueprint Medicines's conference presentation, Nov 15, 2018
Slide 1: NAVIGATOR Study Update CTOS 2018 Annual Meeting
NAVIGATOR Study Update CTOS 2018 Annual Meeting November 15, 2018 Avapritinib precision therapy in advanced GIST
Slide 2: Conference call participants
Conference call participants Jeff Albers Chief Executive Officer, Blueprint Medicines Ben Wolf, MD, PhD SVP Clinical Development, Blueprint Medicines Michael Heinrich, MD Professor of Medicine, Oregon Health and Sciences University 2
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 4: Welcome
Welcome Jeff Albers, Chief Executive Officer
Slide 5: Precision therapies for people with cancer and rare diseases
Precision therapies for people with cancer and rare diseases A NEW WAY OF LOOKING AT KINASE MEDICINES WITH A FOCUS ON CORE AREAS OF EXPERTISE GENOMICALLY DEFINED CANCERS CANCER IMMUNOTHERAPY SELECTIVE NON-SELECTIVE AVAPRITINIB SUTENT® (SUNITINIB) Kinome illustration reproduced courtesy of Cell Signa
Slide 6: Avapritinib is a potent and highly selective KIT and PDGFRA inhibitor
Avapritinib is a potent and highly selective KIT and PDGFRA inhibitor 6 • Ongoing development in advanced GIST and systemic mastocytosis (SM) • Breakthrough Therapy Designations for PDGFRα D842V GIST and advanced SM • Planned NDA in 1H 2019 for PDGFRA-driven and ≥4L GIST • Blueprint Medicines retain
Slide 7: Avapritinib is Highly Active and Well-tolerated in Advanced GIST
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA Michael Heinrich, Margaret von Mehren, Robin L. Jones, Sebastian Bauer, Yoon-Koo Kang, Patrick Schöffski, Ferry Eskens, César Serrano, Philippe A. Cassi
Slide 8: Disclosures
Disclosures • Avapritinib is an investigational agent discovered and currently in development by Blueprint Medicines Corporation (Blueprint Medicines) • Data are preliminary and based on a cutoff date of October 15, 2018 • Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing Phas
Slide 9: Avapritinib kinome selectivity
Avapritinib kinome selectivity Avapritinib: a highly selective and potent KIT/PDGFRA inhibitor for GIST 9 GIST mutation(s) Medical need by mutation Avapritinib biochemical IC50 1 KIT Exon 11 deletion JM domain 1L imatinib is effective 2L sunitinib/3L regorafenib have low ORR/short PFS 0.6 nM KIT Exo
Slide 10: NAVIGATOR Phase 1 study design
NAVIGATOR Phase 1 study design 10 Advanced GIST (N = 46) Part 1 dose escalation Part 2 dose expansion RP2D* KEY OBJECTIVES • Determine MTD/RP2D, safety, PK and clinical activity by line of therapy and mutational status • ORR/DOR per central radiology assessment (mRECIST 1.1) for planned NDA and MAA
Slide 11: Demography and baseline characteristics
Demography and baseline characteristics 11 Parameter All patients (N = 231) Age (years), median (range) 62 (25, 90) GIST mutational subtype, %(n) KIT PDGFR D842V PDGFR non-D842V 72% (167) 24% (56) 4% (8) Metastatic disease, % (n) 89% (205) Largest target lesion size, %(n) ≤5 cm >5–≤10 cm >10 cm Pe
Slide 12: Adverse events ≥20%
Adverse events ≥20% 12 Safety population; all doses (N = 231) AE, % (n) Any Grade Grade 1 Grade 2 Grade 3 Grade 4 Nausea 61% (142) 46% (106) 13% (30) 3% (6) 0 Fatigue 55% (127) 21% (48) 28% (64) 6% (15) 0 Anemia 46% (107) 5% (11) 15% (35) 25% (58) 1% (3) Periorbital edema 40% (93) 34% (79) 6% (13) <
Slide 13: Best response by central radiology in PDGFR D842V GIST
Best response by central radiology in PDGFR D842V GIST 13 98% of patients with tumor reduction PD SD PR CR-100 -80 -60 -40 -20 0 20 Maximum reduction – sum of diameter change from baseline, % n = 56 patients across all dose levels PD, progressive disease; SD, stable disease; PR, partial response; C
Slide 14: ORR and DOR by central radiology in PDGFR D842V GIST
ORR and DOR by central radiology in PDGFR D842V GIST 14 Best response* n = 56 mRECIST 1.1 %(n) [95% CI] ORR 84% (47) [71.7-92.47] CR/PR* 9% (5)/75% (42) SD 16% (9) CBR† 96% (54) [87.7-99.6] DOR 12-month DOR 76.3%; 12-month PFS 81.3% 0 3 6 9 12 15 18 21 24 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Slide 15: Best response by central radiology in ≥4L GIST
Best response by central radiology in ≥4L GIST 15
Slide 16: ORR and DOR by central radiology ≥4L GIST
ORR and DOR by central radiology ≥4L GIST 16 mDOR, median duration of response; NE, not estimatable *1 PR pending confirmation. Patients who have had ≥1 post-baseline radiographic assessment. Response evaluable includes 300 mg and 400 mg. †PR + SD lasting ≥4 months Best response* n = 109 mRECIST 1.1
Slide 17: Best response in 3L/4L regorafenib-naïve GIST
Best response by central radiology in 3L/4L regorafenib-naïve GIST* 17*Similar to Phase 3 trial population (VOYAGER), except that PDGFR D842V patients (ORR 80%) are not included here.
Slide 18: ORR and DOR in 3L/4L regorafenib-naïve GIST
ORR and DOR by central radiology in 3L/4L regorafenib-naïve GIST 18 mDOR 10.2 months (95% CI: 4.2-NE) *All responses are confirmed. Patients who have had ≥1 post-baseline radiographic assessment. Response evaluable includes 300 mg and 400 mg. †PR + SD lasting ≥4 months Non-D842V patients best respon
Slide 19: Best response by mutational profile in ≥4L GIST
Best response by mutational profile in ≥4L GIST 19 -100 -50 0 50 100 Best response (RECIST) PD SD CR PR V654A or T670I positiveV654A and T670I negative n = 109 patients 300/400 mg; baseline genotype per ct-DNA and tumor sequencing Best response* n = 109 V654A or T670I POSITIVE, % (n) (n = 25) V654A
Slide 20: Avapritinib has important clinical activity in advanced GIST
Avapritinib has important clinical activity in advanced GIST 20 PDGFRα D842V n = 56 ≥4L all patients n = 109 3L/4L regorafenib- naïve non-D842V n = 23 2L non-D842V n = 20 ORR (central radiology), % (n) [95% CI] 84% (47) [72-92] 20% (22) [13.1-29.0] 26% (6) [10.2-48.4] 25% (5) [9-49] mDOR (central ra
Slide 21: NAVIGATOR demonstrates favorable tolerability and encouraging clinical activity
• Phase 1 NAVIGATOR study demonstrates favorable tolerability and encouraging clinical activity across lines of therapy – Most AEs were grade 1 or 2, with manageable on-target toxicity – Important efficacy in PDGFRα D842V GIST and refractory, ≥4L GIST supports regulatory filing – Encouraging activit
Slide 22: Acknowledgments
Acknowledgments 22 We would like to thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: • OHSU Knight Cancer Institute • Fox Chase Cancer Center • Royal Marsden Hospital/Institute of Cancer Research • University of Du
Slide 23: Transforming GIST treatment with precision therapy
Transforming GIST treatment with precision therapy Ben Wolf, MD, PhD, SVP Clinical Development
Slide 24: Current GIST treatment paradigm based on sequential therapy
Current GIST treatment paradigm based on sequential therapy ORR, overall response rate; PFS, progression-free survival. 24 1L 2L 3L 4L+ imatinib sunitinib regorafenib No approved therapy ~60% ORR ~19 months PFS ~7% ORR ~6 months PFS ~5% ORR ~4.8 months PFS Precision therapy Multi-kinase therapy Key
Slide 25: Avapritinib is a potentially transformative selective KIT/PDGFRA inhibitor
Avapritinib is a potentially transformative selective KIT/PDGFRA inhibitor Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. All compounds we
Slide 26: NAVIGATOR enables proof-of-concept and expedited regulatory submissions
NAVIGATOR enables proof-of-concept and expedited regulatory submissions Data previously reported at CTOS Annual Meeting in November 2018. Data cutoff date: October 15, 2018. DoR, duration of response. 26 1L 2L 3L 4L+ PDGFRα D842V (~5-6%) 84% ORR 12-month DoR of 76% ► Anticipated initial NDA submissi
Slide 27: Data show potential for improved ORR and durable benefit in 3L GIST
Data show potential for improved ORR and durable benefit in 3L GIST Data previously reported at CTOS Annual Meeting in November 2018. Data cutoff date: October 15, 2018. 27 1L 2L 3L 4L+ PDGFRα D842V (~5-6%) 84% ORR 12-month DoR of 76% All patients 20% ORR 7.3 months median DoR Non-PDGFRα D842V 26% O
Slide 28: Initial data show encouraging activity for avapritinib in 2L GIST
Initial data show encouraging activity for avapritinib in 2L GIST ORR data previously reported at CTOS Annual Meeting in November 2018. Data cutoff date: October 15, 2018. Estimate 5-6% of primary GIST population has a PDGFRα D842V mutation. 28 ORR in unselected population Non-PDGFRα D842V 25% PDGFR
Slide 29: Selection strategy in 2L GIST has the potential to optimize patient outcomes
Selection strategy in 2L GIST has the potential to optimize patient outcomes 29 -100 -50 0 50 100 V654A and T670I negative V654A or T670I positive Increased avapritinib activity in KIT V654A/T670I negative patients (~75-80% of population) NAVIGATOR study ctDNA analysis Estimated frequency of KIT V65
Slide 30: Plan to initiate Phase 3 COMPASS-2L study in 2H 2019
Plan to initiate registration-enabling Phase 3 COMPASS-2L study in 2H 2019 R, randomized 30 R 1:1 avapritinib sunitinib Primary endpoint: PFS Select KIT V654A/T670I negative 2L GIST ctDNA genotyping
Slide 31: Advancing development of avapritinib across all lines of GIST treatment
Advancing development of avapritinib across all lines of GIST treatment 31 PDGFR exon 18 ORR 84%; 12 mo DoR 76% Ph 1 NAVIGATOR Study Plan to submit NDA in 1H 2019 ≥4L ORR 20.2%; mDoR 7.3 months Ph 1 NAVIGATOR Study Plan to submit NDA in 1H 2019 3L/4L regorafenib-naïve Non-D842V initial ORR 26%; mPF
Slide 32: Realizing our vision: 6 registration-enabling studies expected in 2019
DRUG CANDIDATE (TARGET) DISCOVERY PRECLINICAL PHASE 1-2 PIVOTAL1 COMMERCIAL RIGHTS avapritinib (KIT & PDGFRα) BLU-554 (FGFR4) BLU-667 (RET) BLU-782 (ALK2) 3 undisclosed kinase targets Immunokinase targets Realizing our vision: 6 registration-enabling studies expected in 2019 1 Potential for study to
Slide 33: Thank you
(Sbwepriat., Thank you